Efficacy of various antihypertensive drugs in the treatment of hypertension in the patients of end-stage renal disease leading to hemodialysis: a retrospective study

Razi Ahmad; Anwar Habib; Sana Rehman

doi:10.18203/2349-3933.ijam20170112

Authors

Razi Ahmad Department of Pharmacology, HIMSR, Jamia Hamdard, New Delhi, India
Anwar Habib Department of Medicine and Head dialysis unit, HIMSR, Jamia Hamdard, New Delhi, India
Sana Rehman 1Department of Pharmacology, HIMSR, Jamia Hamdard, New Delhi, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20170112

Keywords:

Antihypertensive agent, Amlodipine, Hemodialysis

Abstract

Background: Cardiovascular complications are the leading cause of morbidity and mortality in the patients of end-stage renal disease leading to hemodialysis. Majority of these patients suffers from hypertension and adequate control of blood pressure is a challenge in these patients because of multifactorial etiology and complicated pharmacokinetic changes in these patients. The present study aims is to find out the best possible drug or combination of drugs that can provide better control of blood pressure and improve the quality of life of these patients.

Methods: A retrospective study was carried out on the patients who attended the hemodialysis unit of Hakeem Abdul Hamid Centenary hospital from July 2015 to June 2016 (one year), data on antihypertensive drugs and blood pressure control (pre-dialysis and post-dialysis) were recorded and analyzed.

Results: 68.75% patients on hemodialysis were suffering from hypertension and were on antihypertensive medication. A combination of Amlodipine and clonidine were the most frequently prescribed antihypertensive agents. Muscle cramps an acute rise in blood pressure and hypotension were the most frequently encountered intradialytic complications in these patients.

Conclusions: Although a combination of amlodipine and clonidine was most frequently prescribed antihypertensive medication in these patients these drugs were associated with intradialytic complications like muscle cramps and hypotension. Amlodipine with beta-adrenoceptor blocker (metoprolol or bisoprolol) provided best control of blood pressure in these patients with least intradialytic complications.

Metrics

Metrics Loading ...

References

Heerspink HJ, Ninomiya T, Zoungas S. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis-a systematic review and meta-analysis of randomized controlled trials. Lancet. 2009;373:1009-15.

Paula FM, Peixoto AJ, Pinto LV. Clinical consequences of an individualized dialysate sodium prescription in hemodialysis patients. Kidney Int. 2004;66:1232-8.

Locatelli F, Covic A, Chazot C, Leunissen K, Luno J, Yaqoob M. Hypertension and cardiovascular risk assessment in dialysis patients. Nephrol Dial Transplant. 2004;19(5):1058-68.

Berglund B, Ekblom B. Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. J Intern Med. 1991;229(2):125-30.

WHO. Drug utilization review; world health organization; Geneva 1977.

Rizvi SA, Manzoor K. Causes of chronic renal failure in Pakistan: a single large center experience. Saudi journal of kidney diseases and transplantation. 2002;13:376-9.

Vikrant S, Machhan P, Pandey D. Hemodialysis experience at a tertiary care hospital in Himachal Pradesh. Indian J Nephrol. 2004;14:128-9.

Dordevic V, Stojanovic M, Stefanovic S. Adequacy of hemodialysis in a large university affiliated dialysis center in Serbia. Facta Universitalis. 1999;6:107-11.

Bailie GR, Eisele G, Liu L, Roys E, Kiser M. pattern of medication use in the RRI-CKD: focus on mrdications with cardiovascular effects. Nephrology Dialysis Transplant. 2005;20:1110-5.

Alebiosu CO, Ayodele O, Abbas A, Olutoyin. Chronic renal failure at the Olabisi Onabajo University teaching hospital, Sagamu, Nigeria. African Health Sciences. 2006;6:132-8.

Dash SC, Agarwal SK. Incidence of chronic kidney disease in India. Nephrology Dialysis Transplantation. 2006;21:232-3.

Hecking E, Gresham JL, Rayner HC. Hemodialysis prescription, adherence and nutritional indicators in five European countries: result from the dialysis outcomes and practice patterns study (DOPPS). Nephrology Dialysis Transplantation. 2004;19:100-7.

Oshawa M. Cardiovascular risk factors in hemodialysis patients. Journal Epidemiology. 2005;15:46-59.

Modi GK, Jha V. Incidence of end-stage renal disease in India: a population-based study. Kidney International. 2006;70:2131-3.

Tozawa M, Iseki C, Oshiro S, Higashiuesato Y. Analysis of drug prescription in chronic hemodialysis patients. Nephrology Dialysis Transplantation. 2002;17:1819-24.

Agarwal R, Nissenson AR, Battle D. Prevalence, treatment and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003;115:291-7.

Mazzuchi N, Carbonell E, Cean FJ. Importance of blood pressure control in hemodialysis patient survival. Kidney Int. 2000;58:2147-54.

Takeda A, Toda T, Fujii T, Shinohara S. Discordance of influence of hypertension on mortality and cardiovascular risk in hemodialysis patients. Am J Kidney Dis. 2005;45:112-8.

Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int. 1996;49:1379-85.

Inring JK, Patel UD, Gillespie BS, Hasselblade V. Relationship between interdialytic weight gain and blood pressure among prevalent hemodialysis patients. Am J Kidney Dis. 2007;50:108-18.

He FJ, Macgregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trial. Implications for public health. J Hum Hypertens. 2002;16:761-70.

Rocco MY, Yan G, Heyka RJ. Risk factors for hypetension in chronic hemodislysis patients, baseline data from the HEMO study. Am J Nephrol. 2001;21:280-8.

Fishbane S, Natke E, Maesaka JK. Role of volume overload in dialysis-refractory hypertension. Am J Kidney Dis. 1996; 28(2):257-261.

Agarwal R, Lewis R, Davis JL. Lisinopril therapy for hemodialysis hypertension. Hemodynamic and endocrine responses. Am J Kidney Dis. 2001;38:1245-50.

Zannad F, Kessler M, Lehert P. Prevention of cardiovascular events in end-stage renal disease: result of randomized trial of fosinopril and implications fro future study. Kidney Int. 2006;70:1318-24.

Knoll GA, Sahgal A, Nair RC, Graham J. Renin-angiotensin system blockade and increased risk of hyperkalemia in chronic hemodialysis patients. Am J Med. 2002;112:110-4.

The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure. Arch Inten Med. 1997;157:2413-46.

Sica DA, Gehr TW. Calcium-channel blockers and end-stage renal disease: pharmacokinetic and pharmacodynamic considerations. Curr Opin Nephrol Hypertens. March 2003; 12 (2): 123-31.

Kungys G, Naujoks H, Wanner C. Pharmacokinetics of Amlodipine in hypertensive patients undergoing hemodialysis. Eur J Clin Pharmacol. 2003;59:291-5.

Zachariah PK, Moyer TP, Theobald. The pharmacokinetics of racemic verapamil in patients with impaired renal function. J Clin Pharmacol. 1991;31:45-53.

Satosker RS, Rege NN, Bhardarkar SD. Pharmacology and Pharmacotherapeutics. 24th edition. Popular Prakashan Pvt Ltd. India: 2015;406-407.

Tepel M, Hopfenmueller W, Scholze A, Maler A. Effect of Amlodipine on cardiovascular events in hypertensive hemodialysis patients. Nephrol Dial Transplant. 2008;23:2605-3612.

Kestenbaun B, Gillen DL, Sherrard. Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int. 2002;61:2157-64.

Epstein M, Oster JR. Beta blockers and renal function: a reappraisal. J Clin Hypertens. 1985;1:85-99.

Sugino G, Barg AP. Renal perfusion is preserved during cardioselective beta-blockade with metoprolol in hypertension. Am J Kidney Dis. 1984;3:357-61.

Ljungman S, Wikstrand J. Effects of long-term antihypertensive treatment and aging on renal function and albumin excretion in primary hypertension. Am J Hypertens. 1993;6:554-63.

Seiler KU, Schuster KJ. The pharmacokinetics of metoprolol and its metabolites in dialysis patients. Clin Pharmacokinet. 1980;5:192-8.

Branten AJ, Hilbrands LB, Hamersvelt HW. Renal and systemic effects of atenolol and tertalol in renal transplant recipients on cyclosporine. Nephrol Dial Transplant. 1998;13:423-6.

Agarwal R. Management of hypertension in hemodialysis patient. Hemodialysis International. 2006;10:241-8.

Jula K, Inrig. Antihypertensive Agents in Hemodialysis Patients: A Current Perspective. Semin dial. 2010 May-Jun; 23(3):290-297.

Graffith TF, Chua BS, Allen AS. Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 2003;42:1260-9.